Literature DB >> 12959211

Percutaneous closure of window-type patent ductus arteriosus: using the CardioSEAL and STARFlex devices.

Jacek Bialkowski1, Malgorzata Szkutnik, Jacek Kusa, Joerg Stein.   

Abstract

Transcatheter closure of patent ductus arteriosus is routinely performed using various devices. After the withdrawal of the Rashkind umbrella device from the market, the wide window-type patent ductus arteriosus has been difficult to close percutaneously. Two patients with this condition are presented: a 17-year-old man and a 62-year-old woman with short (4.5- and 5.2-mm-diameter, respectively) ductus. We successfully implanted a 17-mm CardioSEAL device in the 1st patient and a 23-mm STARFlex in the 2nd, with no residual shunt at follow-up (22 and 8 months, respectively). Although these devices (which follow the general design of the Rashkind umbrella) are usually applied to atrial septal defect closure, we believe that CardioSEAL and STARFlex implants could be the treatment of choice in percutaneous treatment.of window-type patent ductus arteriosus.

Entities:  

Mesh:

Year:  2003        PMID: 12959211      PMCID: PMC197326     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  8 in total

1.  Late follow-up of occlusion of the patent ductus arteriosus with the Rashkind device with emphasis on long-term efficacy and risk for infections.

Authors:  R Formigari; A Toscano; I Herraiz; J Bialkowski; A Donti; F M Picchio; R Bermudez-Cañete; L Ballerini
Journal:  Am J Cardiol       Date:  2001-09-01       Impact factor: 2.778

2.  Closure of the patent ductus arteriosus with the amplatzer PDA device: immediate results of the international clinical trial.

Authors:  H J Faella; Z M Hijazi
Journal:  Catheter Cardiovasc Interv       Date:  2000-09       Impact factor: 2.692

3.  Percutaneous closure of the small (less than 2.5 mm) patent ductus arteriosus using coil embolization.

Authors:  P A Cambier; W C Kirby; D C Wortham; J W Moore
Journal:  Am J Cardiol       Date:  1992-03-15       Impact factor: 2.778

4.  Patent ductus arteriosus occlusion using detachable coils.

Authors:  R Bermúdez-Cañete; G Santoro; J Bialkowsky; I Herraiz; R Formigari; M Szkutnik; L Ballerini
Journal:  Am J Cardiol       Date:  1998-12-15       Impact factor: 2.778

5.  Angiographic classification of the isolated, persistently patent ductus arteriosus and implications for percutaneous catheter occlusion.

Authors:  A Krichenko; L N Benson; P Burrows; C A Möes; P McLaughlin; R M Freedom
Journal:  Am J Cardiol       Date:  1989-04-01       Impact factor: 2.778

6.  Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement.

Authors:  J Hung; M J Landzberg; K J Jenkins; M E King; J E Lock; I F Palacios; P Lang
Journal:  J Am Coll Cardiol       Date:  2000-04       Impact factor: 24.094

7.  Nonsurgical closure of patent ductus arteriosus: clinical application of the Rashkind PDA Occluder System.

Authors:  W J Rashkind; C E Mullins; W E Hellenbrand; M A Tait
Journal:  Circulation       Date:  1987-03       Impact factor: 29.690

8.  Extending the limits of transcatheter closure of atrial septal defects with the double umbrella device (CardioSEAL).

Authors:  R Kaulitz; T Paul; G Hausdorf
Journal:  Heart       Date:  1998-07       Impact factor: 5.994

  8 in total
  3 in total

1.  The window ductus: Circulatory arrest as an option for surgical repair.

Authors:  Vijay Agarwal; Muslim Mustaev
Journal:  Ann Pediatr Cardiol       Date:  2010-07

2.  Relationship of high altitude and congenital heart disease.

Authors:  Asif Hasan
Journal:  Indian Heart J       Date:  2016-01-19

3.  Transcatheter Closure of Patent Ductus Arteriosus in Elderly Patients: Initial and One-Year Follow-Up Results-Do We Have the Proper Device?

Authors:  Michal Galeczka; Malgorzata Szkutnik; Jacek Bialkowski; Sebastian Smerdzinski; Mateusz Knop; Adam Sukiennik; Roland Fiszer
Journal:  J Interv Cardiol       Date:  2020-04-29       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.